48 studies found for:    Tardive Dyskinesia
Show Display Options
Rank Status Study
21 Completed Aim to Reduce Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: SD-809;   Drug: Placebo
22 Recruiting Addressing Involuntary Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: SD-809;   Drug: Placebo
23 Terminated Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Condition: Neuroleptic-induced Tardive Dyskinesia
Interventions: Drug: Sarizotan;   Other: Placebo
24 Withdrawn Pyridoxal Kinase Activity in Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: Pyridoxine
25 Completed Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
Conditions: Dyskinesia;   Schizophrenia
Intervention: Drug: eicosapentaenoic acid
26 Unknown  Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
Condition: Dyskinesia, Drug-Induced
Intervention: Drug: aripiprazole
27 Completed Levetiracetam Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: levetiracetam;   Drug: placebo
28 Active, not recruiting The Assessment of Movement Disorders Utilizing Live Two-Way Video
Condition: Tardive Dyskinesia
Intervention: Other: Two way video assessment
29 Enrolling by invitation Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Intervention: Drug: Valbenazine
30 Unknown  Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
Conditions: Dystonia;   Movement Disorder
Intervention: Procedure: deep brain stimulation
31 Completed Movement Disorders Caused by Antipsychotic Drugs in Older Patients
Condition: Dyskinesia, Drug-Induced
Interventions: Drug: Quetiapine;   Drug: Risperidone;   Drug: Olanzapine
32 Active, not recruiting Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Condition: Tardive Dyskinesia
Interventions: Drug: Tetrabenazine;   Drug: Placebo
33 Completed Heart Rate Variability in Response to Metformin Challenge
Conditions: Fibromyalgia;   Mitochondrial Diseases;   Movement Disorders;   Diabetes Mellitus, Type 2
Intervention: Drug: Metformin
34 Recruiting Dysport for the Treatment of OMD
Conditions: Oral Dystonia;   Tardive Dystonia
Intervention: Drug: AbobotulinumtoxinA
35 Recruiting ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
Conditions: Movement Disorders;   Essential Tremor;   Holmes Tremor;   Parkinson's Disease;   Wilson's Disease;   Huntington's Disease;   Dystonia;   Tardive Dyskinesia;   Orofacial Dyskinesias
Intervention: Device: Transcranial ExAblate System
36 Completed Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Tardive Dyskinesia;   Insulin Resistance;   Obesity
Intervention: Drug: Panax Ginseng
37 Unknown  The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
Condition: Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome
Intervention: Drug: Aripiprazole
38 Completed Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation
Condition: Akathisia
Intervention:
39 Recruiting Validation of the Implantation of a New Electrode for the Treatment of Dystonia
Conditions: Generalized Dystonia;   Segmental Dystonia;   Tardive Dystonia
Intervention: Device: Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)
40 Completed Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Condition: Schizophrenia
Interventions: Device: t-VNS verum;   Device: t-VNS placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-48) Show next page of results    Last Page
Indicates status has not been verified in more than two years